Gene therapy biotech sees its stock rocket higher on promising results for rare cases of butterfly disease
Shares of Krystal Biotech took off this morning $KRYS after the little biotech reported promising results from its gene therapy to treat a rare skin disease called epidermolysis bullosa.
Focusing on an update with 4 new patients, researchers spotlighted the success of KB103 in closing some stubborn wounds. Krystal says that of 4 recurring and 2 chronic skin wounds treated with the gene therapy, the KB103 group saw the closure of 5. The 6th — a chronic wound, defined as a wound that had remained open for more than 12 weeks — was partially closed. That brings the total so far to 8 treated wounds, with 7 closures.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
